Core Viewpoint - NeuroSense Therapeutics has strengthened its global intellectual property portfolio for its lead drug candidate PrimeC by securing an Australian patent, which complements an existing U.S. patent and extends exclusivity through October 2042 [1][2][3]. Group 1: Intellectual Property and Patent Strategy - The Australian Patent Office granted Australian Patent No. 2022370513 for PrimeC, which is a significant addition to NeuroSense's global patent protection strategy [1][2]. - The granted patent in Australia follows the approval of the corresponding U.S. patent (12,097,185), enhancing NeuroSense's exclusivity strategy for PrimeC across key global markets [2][3]. - CEO Alon Ben-Noon emphasized that securing patent protection in Australia is crucial for executing the company's global IP protection strategy for PrimeC, which is essential for long-term value creation [3]. Group 2: Product Development and Clinical Readiness - PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to target multiple disease pathways implicated in ALS and Alzheimer's disease [3][7]. - The formulation of PrimeC allows for consistent exposure across various disease pathways, supporting a multi-target disease-modifying approach [3]. - PrimeC is now Phase 3-ready in ALS, following positive results from the Phase 2b PARADIGM trial and FDA clearance of the pivotal Phase 3 protocol [4]. Group 3: Market Context and Unmet Medical Needs - Neurodegenerative diseases, including ALS and Alzheimer's, represent significant unmet medical needs, with limited effective therapeutic options currently available [5]. - ALS affects over 5,000 people annually in the U.S., with a substantial disease burden estimated at $1 billion per year [8]. - Alzheimer's disease impacts more than 30 million people globally, characterized by memory loss and cognitive decline, with a pressing need for disease-modifying treatments [10].

Core Viewpoint - The U.S. International Trade Commission has issued a favorable initial determination for Shoals Technologies Group in its patent infringement complaint against Voltage, confirming that Voltage violated U.S. intellectual property laws by importing infringing products [1][2]. Group 1: Patent Infringement and Legal Proceedings - The ITC's initial finding indicates that Voltage infringed on Shoals' patented Big Lead Assembly (BLA) solutions, which are crucial for utility-scale solar projects [2][3]. - The final determination from the ITC, expected by June 2026, may include a Presidential review and could prevent the importation of infringing trunk bus solutions if upheld [3]. - Shoals is actively pursuing an appeal related to another patent case in the U.S. Court of Appeals to ensure comprehensive protection of its intellectual property [3]. Group 2: Company Background and Market Position - Shoals Technologies Group is a leading manufacturer of advanced electrical infrastructure solutions, focusing on utility-scale solar, battery storage, and data center power systems [4]. - The company has been recognized for its innovative technologies that enhance installation efficiency, safety, and system performance since its founding in 1996 [4]. - Shoals emphasizes the importance of U.S. manufacturing in the energy transition and aims to protect its intellectual property while creating American jobs [3].

Core Viewpoint - Canadian Solar Inc. achieved a significant legal victory against Maxeon Solar Pte. Ltd. regarding patent infringement claims, with the PTAB ruling all claims by Maxeon as invalid [1]. Group 1: Legal Victory - The Patent Trial and Appeal Board (PTAB) ruled in favor of Canadian Solar, invalidating all claims asserted by Maxeon against the company [1]. - This decision underscores the effectiveness of the international intellectual property protection framework and highlights Canadian Solar's strong technological foundation and legal capabilities [2]. Group 2: Company Overview - Canadian Solar is a leading global solar technology and renewable energy company, established in 2001 and headquartered in Kitchener, Ontario [4]. - The company has delivered nearly 170 GW of solar photovoltaic modules globally and has shipped over 16 GWh of battery energy storage solutions, with a contracted backlog of $3.1 billion as of October 31, 2025 [4]. - Canadian Solar has developed approximately 12 GWp of solar power projects and 6 GWh of battery energy storage projects since entering the project development business in 2010, with a diversified pipeline of 25 GWp of solar and 81 GWh of battery energy storage capacity in various development stages [4]. Group 3: Intellectual Property - Canadian Solar has filed over 5,000 patent applications and has been granted more than 4,000 patents, demonstrating its commitment to protecting intellectual property [3]. - The company emphasizes the importance of respecting intellectual property rights and opposes the misuse of patents that lack practical value [3].

Core Insights - The U.S. Court of Appeals for the Fifth Circuit upheld a $194 million award to DXC's subsidiary, CSC, for trade secret misappropriation by Tata Consultancy Services (TCS) [1][2] - The court affirmed that TCS acted willfully and maliciously in misappropriating CSC's trade secrets, with over $100 million awarded in punitive damages due to TCS's repeated deceitful actions [2] Company Commitment - DXC Technology emphasizes its commitment to responsible innovation, ethical conduct, and the protection of intellectual property as fundamental to its operations [3] - The ruling is seen as a validation of DXC's six-year pursuit of legal action to protect its intellectual property, which is crucial for maintaining customer trust [2][3] Leadership Perspective - CEO Raul Fernandez stated that trust, ethics, and responsible innovation are core principles guiding DXC's operations, highlighting the importance of safeguarding mission-critical systems for clients [3] - The company aims to ensure that innovation is deployed responsibly, thereby strengthening customer trust and driving long-term business outcomes [3] Company Overview - DXC Technology is a leading enterprise technology partner that provides software, services, and solutions to global enterprises and public sector organizations, focusing on AI and modernization [4] - The company specializes in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, operating complex technology estates [4]

Core Insights - Adial Pharmaceuticals has announced the publication of an international patent application for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients, with patent protection expected to last until at least 2045 [1][2] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with AD04 being a genetically targeted serotonin-3 receptor antagonist [3] - The company is planning a new Phase 3 clinical trial program for AUD, utilizing a proprietary diagnostic genetic test to identify target genotypes [3] Clinical Development - The ONWARD trial for AD04 has shown promising results in reducing drinking among heavy drinking patients, with no significant safety or tolerability concerns reported [3] - AD04 is also believed to have potential applications in treating other addictive disorders, including Opioid Use Disorder, gambling, and obesity [3]

As filed with the Securities and Exchange Commission on January 12, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphjet Technology (Exact name of registrant as specified in its charter) Cayman Islands 3620 N/A (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) (I.R.S. Employer Identification Number) Lot 3895, Lorong 6D, Kam ...

As filed with the Securities and Exchange Commission on January 12, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphjet Technology (Exact name of registrant as specified in its charter) Cayman Islands 3620 N/A (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) (I.R.S. Employer Identification Number) Lot 3895, Lorong 6D, Kam ...

Core Viewpoint - Scilex Holding Company has appointed Kasowitz LLP and its founding partner Marc Kasowitz as its litigation and intellectual property counsel to enhance its legal capabilities in protecting and advancing its proprietary pharmaceutical assets and development pipeline [1][2][3]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][7]. - The company targets high unmet needs and large market opportunities with non-opioid therapies, aiming to improve patient outcomes [4]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief associated with postherpetic neuralgia [4]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [4]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [4]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, which has completed a Phase 2 trial and also received Fast Track status [6]. - SP-104, a novel low-dose delayed-release naltrexone for fibromyalgia treatment [6]. Legal Counsel Appointment - Kasowitz LLP will provide advice on complex commercial litigation, patent litigation, intellectual property enforcement, and licensing matters [2]. - Marc Kasowitz is recognized for his expertise in high-stakes intellectual property and complex commercial litigation, enhancing Scilex's legal strategy [3].

Core Viewpoint - Datavault AI Inc. has strengthened its intellectual property and litigation capabilities by appointing Kasowitz LLP to enhance the protection and enforcement of its patented technologies in AI, data monetization, and digital twin sectors [1] Group 1: Company Developments - Datavault AI Inc. is a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies [1] - The company has appointed Kasowitz LLP and Marc Kasowitz to work alongside its existing counsel [1] - The focus of this appointment is to advise on intellectual property litigation, patent strategy, and technology-related disputes [1] Group 2: Technology Focus - The company is involved in proprietary technologies related to AI, data science, acoustic transmission, digital twin, and data monetization [1] - The appointment aims to bolster the protection and enforcement of these technologies [1]

Core Viewpoint - The Shanghai Xuhui District Procuratorate's third procuratorial department is focusing on integrating party building with business development in the artificial intelligence sector, aiming to support the sustainable growth of leading industries through innovative legal frameworks and community engagement [2][3]. Group 1: Integration of Legal and Technological Development - The party branch emphasizes the integration of political and business capabilities, utilizing red resources and various educational formats to enhance knowledge of party history, procuratorial history, and intellectual property law [2]. - A model for intellectual property protection has been recognized as one of the top ten innovative cases in Shanghai, showcasing the effectiveness of the integrated approach to legal education and case studies [2]. Group 2: Innovation and Risk Management - The establishment of a "Legal Vice Principal" role within the "Model Speed Space" aims to enhance legal oversight and risk management for AI enterprises, proposing 41 measures for operational risk prevention [3]. - A collaborative platform for intellectual property protection has been created, focusing on comprehensive protection strategies for foreign-related intellectual property [3]. Group 3: Talent Development and Professional Training - The party branch is integrating party groups with specialized case handling teams to enhance the effectiveness of legal services, encouraging members to take leadership roles in significant projects [4]. - There is a focus on cultivating high-caliber, multidisciplinary talent through dual training in political and business skills, particularly in handling complex cases related to AI and intellectual property [4]. Group 4: Community Engagement and Legal Services - Recent outreach efforts by the procuratorial staff included visits to local tech enterprises to provide legal services, demonstrating a commitment to supporting the innovation ecosystem [5].